Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Darunavir

FDA-approved product (tablet, oral), marketed as Darunavir, Prezista.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Darunavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
FDA pharmacologic class
Protease Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE10

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Darunavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Darunavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

    NCT01367210 · start 2011-06

    Registered record
    Registry ID
    NCT01367210
    Conditions
    HIV Infection
    Interventions
    Maraviroc, Darunavir/r; current antiretroviral therapy with 3 drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-06
    Completion
    2015-06
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionMaraviroc, Darunavir/r; current antiretroviral therapy with 3 drugs
    PhasePhase 4
    Registry statusTerminated

  • TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

    NCT01323257 · start 2011-03

    Registered record
    Registry ID
    NCT01323257
    Conditions
    Hepatitis C Virus
    Interventions
    erythromycin; Ritonavir; TMC435; Darunavir; TMC435; erythromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-08
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    Interventionerythromycin; Ritonavir; TMC435; Darunavir +2 more
    PhasePhase 1
    Registry statusCompleted

  • Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

    NCT01294761 · start 2011-02

    Registered record
    Registry ID
    NCT01294761
    Conditions
    HIV Infections
    Interventions
    Raltegravir, Darunavir/r
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-02
    Completion
    2013-12
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRaltegravir, Darunavir/r
    PhaseNot applicable
    Registry statusCompleted

  • Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.

    NCT01258439 · start 2010-11

    Registered record
    Registry ID
    NCT01258439
    Conditions
    HIV; Cardiovascular Disease
    Interventions
    raltegravir plus truvada; Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-11
    Completion
    2014-07
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Cardiovascular Disease
    Interventionraltegravir plus truvada; Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
    PhasePhase 4
    Registry statusCompleted

  • The First Failure Study

    NCT01118871 · start 2010-05

    Registered record
    Registry ID
    NCT01118871
    Conditions
    HIV; HIV Infections
    Interventions
    Darunavir, Ritonavir, Truvada; Darunavir, Ritonavir and Etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-05
    Completion
    2013-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    InterventionDarunavir, Ritonavir, Truvada; Darunavir, Ritonavir and Etravirine
    PhasePhase 4
    Registry statusTerminated

  • Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

    NCT01073761 · start 2010-04

    Registered record
    Registry ID
    NCT01073761
    Conditions
    HIV; HIV Infections
    Interventions
    darunavir/ritonavir then atazanavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    Interventiondarunavir/ritonavir then atazanavir/ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

    NCT02097381 · start 2010-04

    Registered record
    Registry ID
    NCT02097381
    Conditions
    HIV Infection
    Interventions
    Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2014-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionTenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
    PhaseNot applicable
    Registry statusUnknown

  • Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

    NCT00936793 · start 2009-07-06

    Registered record
    Registry ID
    NCT00936793
    Conditions
    HIV; Asthma
    Interventions
    Darunavir; Ritonavir; Beclomethasone Dipropionate HFA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07-06
    Completion
    2011-06-10
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Asthma
    InterventionDarunavir; Ritonavir; Beclomethasone Dipropionate HFA
    PhasePhase 1
    Registry statusCompleted

  • A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

    NCT00827112 · start 2009-03

    Registered record
    Registry ID
    NCT00827112
    Conditions
    Human Immunodeficiency Virus-1
    Interventions
    maraviroc; maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2011-07
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus-1
    Interventionmaraviroc; maraviroc
    PhasePhase 2
    Registry statusCompleted

  • GSK1349572 Drug Interaction Study With Protease Inhibitors

    NCT00774735 · start 2008-10

    Registered record
    Registry ID
    NCT00774735
    Conditions
    Healthy Subjects; Infection, Human Immunodeficiency Virus
    Interventions
    GSK1349572; GSK1349572
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects; Infection, Human Immunodeficiency Virus
    InterventionGSK1349572; GSK1349572
    PhasePhase 1
    Registry statusCompleted

  • A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

    NCT00783484 · start 2008-10

    Registered record
    Registry ID
    NCT00783484
    Conditions
    Healthy Volunteers
    Interventions
    PF-03716539; PF-03716539; PF-03716539; Placebo; PF-03716539; PF-03716539; PF-03716539; Placebo; Midazolam; Midazolam + PF-03716539 (100 mg); Midazolam + PF-03716539 (50 mg); Darunavir; Darunavir + PF-03716539; Maraviroc; Maraviroc +PF-03716539; Maraviroc; Maraviroc +PF-03716539
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-05
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPF-03716539; PF-03716539; PF-03716539; Placebo +13 more
    PhasePhase 1
    Registry statusCompleted

  • Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

    NCT00756730 · start 2008-09

    Registered record
    Registry ID
    NCT00756730
    Conditions
    HIV Infections
    Interventions
    ATV/r; DRV/r
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2011-06
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionATV/r; DRV/r
    PhasePhase 4
    Registry statusCompleted

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

    NCT02251795 · start 2007-08

    Registered record
    Registry ID
    NCT02251795
    Conditions
    Healthy
    Interventions
    Tipranavir; Ritonavir; Darunavir; Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-08
    Completion
    Not recorded
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir; Ritonavir; Darunavir; Aspirin
    PhasePhase 1
    Registry statusCompleted

  • TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

    NCT00255099 · start 2005-12

    Registered record
    Registry ID
    NCT00255099
    Conditions
    HIV
    Interventions
    TMC125; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-07
    Enrolment
    593

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTMC125; Placebo
    PhasePhase 3
    Registry statusCompleted